BioSpace News Archive

Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”) announced today positive preliminary results from its Phase 1b study of human allogeneic adipose-derived mesenchymal stem cells (COVI-MSC™) for patients suffering from COVID-19-induced acute respiratory distress (ARD) or acute respiratory distress syndrome (ARDS).

Scopus BioPharma Inc. announced the pricing of a $9 million follow-on public offering. The offering consists of 1,000,000 shares of common stock at a public offering price of $9.00 per share.

TransEnterix, Inc. announced that, due to demand, the underwriter has agreed to increase the size of the previously announced offering and purchase on a firm commitment basis 23,083,333 shares of common stock of the Company at a public offering price of $3.00 per share, less underwriting discounts and commissions.

As part of the U.S. Food and Drug Administration’s continuing efforts to protect consumers from potentially dangerous or subpotent hand sanitizers, the agency has placed all alcohol-based hand sanitizers from Mexico on a countrywide import alert to help stop products that appear to be in violation from entering the U.S. until the agency is able to review the products’ safety.

For many people, winter skin probably conjures up images of dry, cracked hands, flaky skin, and windburn.

Psychemedics Corporation announced that Andrew Limbek has joined the Company as Vice President, Controller.

For the third year in a row, CooperCompanies has been designated as Great Place to Work-Certified™ organization based on a detailed evaluation of workplace culture and the employee experience.

TransEnterix, Inc. (NYSE American: TRXC) (“TransEnterix” or the “Company”), a medical device company that is digitizing the interface between the surgeon and the patient to improve minimally invasive surgery, today announced that it has entered into an underwriting agreement with H.C. Wainwright & Co.

Today, Biosenta realized its first purchase order and payment from the supply and purchase agreement with SANITIZATION 360.

Samsung Biologics (KRX: 207940.KS) announced another successful Investigational New Drug (IND) clearance from the FDA for its client to begin clinical trials on a cancer immunotherapy, furthering the company’s track record as a premiere CDO service provider in the global market.